Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats

Journal of Parkinson's disease

Volumn 4, Issue 3, 2014, Pages 349-360

  Barnum, Christopher J ^a   Chen, Xi ^a   Chung, Jaegwon ^a   Chang, Jianjun ^a   Williams, Martha ^a   Grigoryan, Nelly ^a   Tesi, Raymond J ^a   Tansey, Malú G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

XPro reg 1595 ; 6 OHDA; astrocytes; inflammation; microglia; Parkinson's disease; substantia nigra; tumor necrosis factor

Indexed keywords

OXIDOPAMINE; TUMOR NECROSIS FACTOR ALPHA; XENP 1595;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; CELL COUNT; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; ENCEPHALITIS; GENETICS; GLIOSIS; MALE; PARKINSONIAN DISORDERS; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ANIMALS; BLOOD-BRAIN BARRIER; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; ENCEPHALITIS; GLIOSIS; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964312421     PISSN: None     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-140410     Document Type: Article

References (0)